IGF-1 DES exhibits increased in vitro bioactivity due to its reduced affinity for IGFBPs, allowing for more unbound IGF-1 to interact directly with target tissues. This distinctive quality enables IGF-1 DES to reach high local concentrations, especially beneficial for potential CNS applications. In neurological research, it has shown promise for supporting glial cell proliferation and neuronal repair mechanisms, making it a target of interest for therapeutic approaches aimed at enhancing endogenous recovery pathways in brain injury.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about IGF DES by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.